A Phase 2 Clinical Trial of Nalirifox as Neoadjuvant Treatment for Patients With Borderline Resectable Pancreatic Ductal Adenocarcinoma (Nectar Study)
Latest Information Update: 10 Jul 2025
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms Nectar Study
Most Recent Events
- 02 Jul 2025 Planned initiation date (estimated date of first participant enrollment) changed from 1 Jun 2025 to 1 Aug 2025.
- 02 Jul 2025 Status changed from not yet recruiting to recruiting.
- 06 Apr 2025 Planned initiation date changed from 1 Mar 2025 to 1 Jun 2025.